Division of Child Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Comprehensive Epilepsy Center, Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Epilepsy Res. 2024 Sep;205:107407. doi: 10.1016/j.eplepsyres.2024.107407. Epub 2024 Jul 6.
Thalamic neuromodulation has emerged as a treatment option for drug-resistant epilepsy (DRE) with widespread and/or undefined epileptogenic networks. While deep brain stimulation (DBS) and responsive neurostimulation (RNS) depth electrodes offer means for electrical stimulation of the thalamus in adult patients with DRE, the application of thalamic neuromodulation in pediatric epilepsy remains limited. To address this gap, the Neuromodulation Expert Collaborative was established within the Pediatric Epilepsy Research Consortium (PERC) Epilepsy Surgery Special Interest Group. In this expert review, existing evidence and recommendations for thalamic neuromodulation modalities using DBS and RNS are summarized, with a focus on the anterior (ANT), centromedian(CMN), and pulvinar nuclei of the thalamus. To-date, only DBS of the ANT is FDA approved for treatment of DRE in adult patients based on the results of the pivotal SANTE (Stimulation of the Anterior Nucleus of Thalamus for Epilepsy) study. Evidence for other thalamic neurmodulation indications and targets is less abundant. Despite the lack of evidence, positive responses to thalamic stimulation in adults with DRE have led to its off-label use in pediatric patients. Although caution is warranted due to differences between pediatric and adult epilepsy, the efficacy and safety of pediatric neuromodulation appear comparable to that in adults. Indeed, CMN stimulation is increasingly accepted for generalized and diffuse onset epilepsies, with recent completion of one randomized trial. There is also growing interest in using pulvinar stimulation for temporal plus and posterior quadrant epilepsies with one ongoing clinical trial in Europe. The future of thalamic neuromodulation holds promise for revolutionizing the treatment landscape of childhood epilepsy. Ongoing research, technological advancements, and collaborative efforts are poised to refine and improve thalamic neuromodulation strategies, ultimately enhancing the quality of life for children with DRE.
丘脑神经调节已成为治疗耐药性癫痫 (DRE) 的一种选择,这种疾病具有广泛和/或未定义的致痫网络。虽然深部脑刺激 (DBS) 和反应性神经刺激 (RNS) 深度电极为 DRE 成年患者提供了电刺激丘脑的手段,但丘脑神经调节在儿科癫痫中的应用仍然有限。为了解决这一差距,在儿科癫痫研究联盟 (PERC) 癫痫手术特别兴趣小组内成立了神经调节专家协作组。在这个专家综述中,总结了使用 DBS 和 RNS 的丘脑神经调节模式的现有证据和建议,重点关注丘脑的前核 (ANT)、中央核 (CMN) 和丘脑枕核。迄今为止,只有 DBS 刺激 ANT 基于关键的 SANTE(丘脑前核刺激治疗癫痫)研究结果,获得了 FDA 批准用于治疗成年 DRE 患者。其他丘脑神经调节适应症和靶点的证据较少。尽管缺乏证据,但 DRE 成年患者对丘脑刺激的积极反应导致其在儿科患者中被超适应证使用。尽管由于小儿癫痫和成人癫痫之间的差异需要谨慎,但儿科神经调节的疗效和安全性似乎与成人相当。事实上,CMN 刺激越来越被接受用于全面性和弥漫性癫痫发作,最近完成了一项随机试验。对于颞叶加后部象限癫痫,使用丘脑枕刺激也越来越受到关注,欧洲正在进行一项临床试验。丘脑神经调节的未来有望彻底改变儿童癫痫的治疗格局。正在进行的研究、技术进步和合作努力将使丘脑神经调节策略得到改进和完善,最终提高 DRE 儿童的生活质量。